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Paraquat (PQ) is a herbicide that preferentially accumulates in the lung and exerts its cytotoxicity via the generation of reactive
oxygen species (ROS). There is no speciﬁc treatment for paraquat poisoning. Attempts have been made to increase the antioxidant
status in the lung using antioxidants (e.g., superoxide dismutase, vitamin E, N-acetylcysteine) but the outcome from such
treatments is limited. Encapsulation of antioxidants in liposomes improves their therapeutic potential against oxidant-induced
lung damage because liposomes facilitate intracellular delivery and prolong the retention of entrapped agents inside the cell. In
the present study, we compared the eﬀectiveness of conventional N-acetylcysteine (NAC) and liposomal-NAC (L-NAC) against
PQ-induced cytotoxicity and examined the mechanism(s) by which these antioxidant formulations conferred cytoprotection. The
eﬀectsofNACorL-NACagainstPQ-inducedcytotoxicityinA549cellswereassessedbymeasuringcellularPQuptake,intracellular
glutathione content, ROS levels, mitochondrial membrane potential, cellular gene expression, inﬂammatory cytokine release and
cell viability. Pretreatment of cells with L-NAC was signiﬁcantly more eﬀective than pretreatment with the conventional drug in
reducingPQ-inducedcytotoxicity,asindicatedbythebiomarkersusedinthisstudy.OurresultssuggestedthatthedeliveryofNAC
as a liposomal formulation improves its eﬀectiveness in counteracting PQ-induced cytotoxicity.
1.Introduction
Paraquat (PQ) is a herbicide that preferentially accumulates
in the lung and exerts its cytotoxic eﬀects via the generation
of reactive oxygen species (ROS) [1–3]. Many studies have
focused on increasing the antioxidant status in the lung
to protect against PQ injury using various antioxidants,
including antioxidant enzymes (e.g., SOD), vitamins (e.g.,
ascorbic acid, α-tocopherol), and low-molecular-weight
thiol-containing antioxidants (e.g., glutathione (GSH), N-
acetylcysteine (NAC)) but the outcomes from such treat-
ments are limited or without success [2–11]. The failure of
these antioxidants to seriously modify the toxicity of the
herbicide has been attributed mostly to their inability to
cross cell membrane barriers and/or to their rapid clearance
from cells [3, 4, 6, 7, 10, 11]. In recent years, it has
been demonstrated that the encapsulation of antioxidants
in liposomes improves their therapeutic potential against
oxidant-induced lung damage, including PQ pulmonary
toxicity, because liposomes facilitate intracellular delivery
and prolong the retention time of entrapped agents inside
the cell [3, 6, 12–15].
Liposomes are phospholipid vesicles composed of lipid
bilayers enclosing an aqueous compartment. Hydrophilic
molecules can be encapsulated in the aqueous spaces, and
lipophilic molecules can be incorporated into the lipid
bilayers. Liposomes, in addition to their use as artiﬁcial
membrane systems, are used for the selective delivery of
antioxidants and other therapeutic drugs to diﬀerent tissues
in suﬃcient concentrations to be eﬀective in ameliorating
tissue injuries. The relative ease in incorporating hydrophilic
and lipophilic therapeutic agents into liposomes, the possi-
bility of directly delivering liposomes to an accessible body
site, such as the lung, and the relative nonimmunogenicity
and low toxicity of liposomes have rendered the liposomal
system highly attractive for drug delivery [3, 12, 16].2 Journal of Toxicology
In the present study, we compared the eﬀectiveness of
conventional NAC and liposomal-NAC (L-NAC) against
PQ-induced cytotoxicity and examined the mechanism(s)
by which these antioxidant formulations conferred their
cytoprotection. N-Acetylcysteine is a low-molecular-weight
thiol-containing antioxidant with free radical-scavenging
properties [3, 17, 18] attributed to the nucleophilicity and
redox interactions of its thiol group [17, 18]. Additionally,
NAC is a source of cysteine, often the limiting precursor
of de novo GSH synthesis [17, 19, 20]. Glutathione is an
important antioxidant as it is the most abundant nonprotein
thiol present in living cells, and its levels are commonly
used as an indicator of intracellular antioxidant status.
Furthermore, NAC has been shown to inﬂuence redox-
sensitive cell-signalling and transcription pathways, such as
NF-κB (which regulates proinﬂammatory genes), the p38,
ERK1/2, SAPK/JNK, c-Jun, and c-Fos pathways, among
others, in a wide variety of diﬀerent systems [17, 21, 22].
N-Acetylcysteine has been shown to promote cell growth
and survival by activating the MAPK pathway in response
to ROS-induced injuries (which normally lead to growth
arrest and apoptosis) and is able to limit inﬂammatory
processes, such as the release of proinﬂammatory cytokines
[22]. These actions may play a role in its cytoprotective
eﬀect. Accordingly, the cytoprotective eﬀects of NAC or L-
NAC against PQ-induced cytotoxicity in A549 human lung
adenocarcinomacellswereassessedbymeasuringcellularPQ
uptake,intracellularGSHcontent,ROSlevels,mitochondrial
membrane potential, cellular gene expression, inﬂammatory
cytokine release, and cell viability. A549 cells possess many
important biological properties ofthealveolarepithelial type
II cell [23, 24] and have been shown to be useful for studying
the metabolic and macromolecule processing contributions
of alveolar type II cells to mechanisms of drug delivery at the
pulmonary epithelium [25].
2.MaterialsandMethods
2.1. Cell Culture and Chemicals. Human alveolar type II-like
epithelial A549 cells (ATCC no. CCL-185, American Type
Culture Collection, Manassas, Va, USA) were maintained
in Costar 0.2μm vent cap cell culture ﬂasks (Corning,
Corning, NY, USA) with standard Dulbecco’s modiﬁed
Eagle’s medium nutrient mixture F-12 Ham (Sigma-Aldrich,
St. Louis, Mo, USA) supplemented with 10% iron-fortiﬁed
bovine calf serum (SAFC Biosciences, Lenexa, Kan, USA),
2mMl-glutamine(Gibco,Carlsbad,Calif,USA),andantibi-
otic/antimycotic (100U/mL penicillin, 100μg/mL strepto-
mycin, and 0.25μg/mL amphotericin B; Gibco). Cultures
were incubated at 37◦C in a humidiﬁed atmosphere of 5%
CO2 in air and subcultured when 80% conﬂuent. Prior
to plating, cell counts and viabilities were assessed using
a Vi-Cell XR Cell Viability Analyzer (Beckman Coulter,
Mississauga, ON, Canada). Paraquat (Paraquat dichloride
x-hydrate, Sigma-Aldrich) was dissolved in distilled water
and diluted with culture media to prepare speciﬁc treatment
concentrations. Experiments were performed using serum-
free media.
To determine the cytotoxicity of NAC alone, cells were
treated with control media or media containing diﬀerent
concentrations of NAC (0 to 50mM ﬁnal NAC concen-
trations). To determine the eﬀe c to fN A Co rL - N A Co n
t h et o x i c i t yo fP Q ,c e l l sw e r eﬁ r s tp r e t r e a t e dw i t hc o n t r o l ,
empty liposomes- (EL-) NAC-, or L-NAC-containing media
(5.0mM for 4h), followed by treatment with control or PQ-
containing media.
2.2. N-Acetylcysteine (NAC) Preparation. NAC (N-acetyl-
L-cysteine, SigmaUltra > 99% TLC; Sigma-Aldrich) was
dissolved in PBS and adjusted to pH 7.4 to produce a 0.1M
stock solution. Following ﬁlter sterilization (0.2μm pore-size
ﬁlters), speciﬁc volumes of N-acetylcysteine stock solution
were added to culture media for the pretreatment/treatment
of cells. NAC stocks were made fresh daily.
2.3. Liposomal-N-Acetylcysteine Preparation. Liposomal-N-
acetylcysteine (L-NAC) was prepared from a mixture of
DPPC (dipalmitoylphosphatidylcholine) and NAC in a 7:3
molar ratio by using a dehydration-rehydration method as
described in [13]. Liposomal vesicle size was determined
with a Submicron Particle Sizer (Nicomp Model 270) fol-
lowing rehydration and was found to have a mean diameter
of 181.5 ± 19.6nm. The encapsulation eﬃciency of NAC by
DPPC-liposomes was measured as 18.5%.
2.4. Cell Viability. Cell viability was measured with the
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay as previously described in [26]. Viabilities of
challenged cells were assessed relative to control cells.
2.5. Determination of Intracellular NAC and PQ Con-
centration with Ultraperformance Liquid Chromatography
(UPLC). The intracellular levels of NAC, PQ, and GSH were
determined by an ultraperformance liquid chromatographic
(UPLC) method using a Waters Acquity system equipped
with a binary solvent manager, an automated sample man-
ager, and a photodiode array detector (Waters, Milford, Mss,
USA) as described previously by Mitsopoulos and Suntres
[26]. Brieﬂy, after each treatment, cells were harvested via
trypsinization, washed twice with phosphate-buﬀered saline
(PBS), lysed via sonication (20s, 100% amplitude; Sonic
Dismembrator Model 500, Fisher Scientiﬁc, Pittsburgh,
Pa, USA), centrifuged, and then passed through a 0.2μm
ﬁlter. The ultraﬁltrate was injected onto an Acquity UPLC
H S ST 3a n a l y t i c a lc o l u m n( 2 . 1m mI . D .× 150mm length,
1.8μm particles) with a Vanguard 2.1mm I.D. × 5mm
length guard column, at 30◦C. The mobile phase consisted
of 23mM ammonium formate (pH 3) at a ﬂow rate
of 0.250mL/min. NAC, PQ, and GSH were measured at
wavelengths of 200.3, 257.7, and 202.1nm, respectively, and
values were normalized to total protein using the Micro
Lowry Total Protein Kit-Peterson’s Modiﬁcation (Sigma-
Aldrich), in accordance with the manufacturer’s instruc-
tions.Journal of Toxicology 3
2.6. Determination of Reactive Oxygen Species Levels. The
intracellular levels of reactive oxygen species were deter-
mined by staining the cells with CM-H2DCFDA (5-(and
6-)chloromethyl-2 ,7 -dichlorodihydroﬂuoresceindiacetate,
acetyl ester) (Molecular Probes, Eugene, Ore, USA) in PBS as
previously described in [26]. Flow cytometric analysis was
performed using a BD FACSCalibur Flow Cytometer (BD
Biosciences, San Jose, Calif, USA) with BD CellQuest Pro
Software. A minimum of 10,000 gated events were acquired
per sample.
2.7. Measurement of Mitochondrial Membrane Potential.
Mitochondrial membrane potential was assessed using the
MitoProbe JC-1 Assay Kit for Flow Cytometry (Molecular
Probes). Following challenge, cells were washed with PBS
and stained for 30 minutes with JC-1 (5,5 ,6,6 -tetrachloro-
1,1 ,3,3 -tetraethylbenzimidazolylcarbocyanine iodide), a
cationic dye that exhibits potential-dependent accumulation
in mitochondria, under standard incubation conditions.
Stained cells were detached from the plate surface and
suspended in PBS for ﬂow cytometric analysis using
the FL1-H and FL2-H channels of a BD FACSCalibur
Flow Cytometer (BD Biosciences) with BD CellQuest
Pro software. A minimum of 10,000 gated events were
acquired per sample. Mitochondrial depolarization was
indicated by decreased red ﬂuorescence intensity due to
concentration-dependent formation of red ﬂuorescent
J-aggregates.
2.8. Gene Expression Analysis. Gene array analysis of cells
challenged with 0.25mM PQ for 4h following pretreatment
with control, NAC-containing or L-NAC-containing media
(5.0mM for 4h) was performed as detailed previously in
[26]usingtheHumanStressandToxicityPathwayFinderRT2
Proﬁler PCR Array (Table 1; SA Biosciences).
Conventional RT-PCR analysis of cells challenged as
indicated previously was performed using the RT2 qPCR
Primer Assays (Table 2; SA Biosciences). The methodology
was carried out similar to that outlined for the gene arrays
with the exception that 1μL of the appropriate primer was
manually added to each well of the iCycler iQ 96-well PCR
Plates (Bio-Rad) and was covered with Microseal “B” Film
(Bio-Rad).
2.9. Measurement of Cytokine Levels. Cells seeded into sterile
25cm2 culture ﬂasks (Corning) at 1.35 × 106 cells/ﬂask
were incubated to 80% conﬂuence overnight, then washed
with PBS and pretreated with control, NAC-containing
or L-NAC-containing media (5.0mM for 4h) followed by
challenge with control or PQ-containing media (0.25 or
1.0mM for 4h). Following incubation, media of treated
cells were analyzed for cytokine levels using a Human Grp
I Cytokine 7-Plex Panel kit (Bio-Rad) speciﬁc for interleukin
(IL)-1β, IL-6, IL-8, IL-10, IL-15, TNF-α, and eotaxin, using
a Bio-Plex 200 System (Bio-Rad) with Bio-Plex Manager
software in accordance with the manufacturer’s instruc-
tions.
2.10. Statistics. Data are presented as mean ± S.E.M (n ≥
3) and analyzed for statistical signiﬁcance using the paired
Student’s t-test, with P<. 05 considered signiﬁcant. For
normalized data, a paired one-sample t-test was performed
comparing means to a hypothetical mean of 1 (P<. 05).
3. Results
3.1. Eﬀect of NAC on Viability of A549 Cells. Challenge of
A549 cells with NAC at concentrations ranging from 0 to
10mMdidnothaveanyeﬀectoncellviability24hafterNAC
exposure. However, a 30% decrease in viability relative to
controlcellswasobservedfollowingtreatmentwith50.0mM
NAC (Figure 1(a)). A NAC concentration of 5.0mM was
used for all subsequent experiments.
3.2. Uptake of NAC in A549 Cells. T h eu p t a k eo fN A Cb y
A549 cells was assessed using UPLC following treatment
with 5.0mM NAC- or L-NAC-containing media for 0, 1, 2,
4, 8, and 24h (Figure 1(b)). Treatment of A549 cells with
conventional NAC resulted in increased NAC uptake up to
2h posttreatment; thereafter, levels remained unchanged up
to 24h posttreatment. Cells treated with L-NAC exhibited
increased uptake over time, with maximal levels achieved
following 4h treatment. Under all investigated conditions,
the uptake of NAC by A549 cells was signiﬁcantly greater
following treatment with the L-NAC formulation compared
to NAC.
3.3. Eﬀect of NAC and L-NAC Pretreatment on Cell Via-
bility after PQ Challenge. Challenge of A549 cells with
PQ resulted in concentration-dependent decreases in cell
viability (Figure 2). Viability of cells challenged with PQ (0.1
and 0.5mM) for 24h was higher in those cells pretreated
with L-NAC. In contrast, pretreatment with NAC or empty
liposomes (EL) did not confer any observable eﬀect on cell
viability of PQ-challenged cells under these conditions.
3.4. Eﬀect of NAC and L-NAC Pretreatment on Cellular Redox
Status and PQ Uptake following PQ Challenge. Exposure of
cells to increasing concentrations of PQ for 24h signiﬁcantly
decreased intracellular GSH content, which correlated with
increases in cellular PQ uptake, as measured by UPLC
(Figure 3). In general, pretreatment with L-NAC but not
NAC resulted in lower PQ-induced depletion in the levels of
intracellular GSH content of cells. Pretreatment with NAC
or L-NAC had no eﬀect on the linear (R2 = 0.969) uptake of
PQ in A549 cells challenged with increasing concentrations
of PQ (Figure 3(b)). ROS levels increased following PQ
exposure (Figure 3(c)), but pretreatment with NAC or L-
NAC signiﬁcantly reduced levels of ROS in 0.25 and 1.0mM
PQ-challenged cells (4h) to either basal or subbasal levels
as assessed via ﬂow cytometric analysis of CM-H2DCFDA-
stained cells (Figure 3(c)).
3.5. Eﬀect of NAC or L-NAC Pretreatment on Mitochondrial
Membrane Potential following PQ Challenge. The mitochon-
drial membrane potential of cells challenged with 0.25mM4 Journal of Toxicology
Table 1: Relative expression, via microarray analysis, of genes involved with cellular stress and toxicity in cells challenged with 0.25mM
PQ for 4h following pretreatment with control, NAC-containing, or L-NAC-containing media. Genes are listed in order of decreasing fold
change in cells pretreated with control media and challenged with PQ. Fold change is expressed relative to untreated control cells using the
housekeeping genes B2M, HPRT1, RPL13A, and GAPDH. Note. the proposed housekeeping gene ACTB was signiﬁcantly altered following
PQ challenge, and was not used in this capacity in our study. n = 3 independent experiments.
GeneBank
accession no. Gene name Symbol
Fold change
Control
media
+P Q
P value NAC
+P Q P value LNAC
+P Q P value
Oxidative/metabolic stress
NM 005953 Metallothionein 2A MT2A 1.17 0.127 −1.07 0.616 1.33 0.229
NM 002133 Heme oxygenase (decycling) 1 HMOX1 1.14 0.531 1.34 0.170 −1.16 0.456
NM 000962
Prostaglandin-endoperoxide synthase 1
(prostaglandin G/H synthase and
cyclooxygenase)
PTGS1 1.10 0.671 1.34 0.208 1.50 0.026∗∗
NM 001885 Crystallin, alpha B CRYAB 1.07 0.847 1.36 0.190 1.18 0.510
NM 002574 Peroxiredoxin 1 PRDX1 1.07 0.505 1.05 0.367 1.04 0.662
NM 000454 Superoxide dismutase 1, soluble
(amyotrophic lateral sclerosis 1 (adult)) SOD1 1.04 0.343 1.05 0.332 −1.07 0.200
NM 000581 Glutathione peroxidase 1 GPX1 1.01 0.812 1.05 0.395 −1.08 0.286
NM 000849 Glutathione S-transferase M3 (brain) GSTM3 −1.02 0.833 −1.09 0.600 −1.03 0.743
NM 001752 Catalase CAT −1.03 0.740 −1.31 0.136 −1.16 0.168
NM 000637 Glutathione reductase GSR −1.08 0.594 −1.57 0.098 −1.46 0.111
NM 005809 Peroxiredoxin 2 PRDX2 −1.12 0.528 −1.01 0.892 −1.22 0.573
NM 001461 Flavin-containing monooxygenase 5 FMO5 −1.28 0.154 −1.53 0.072 −1.60 0.065
NM 000499 Cytochrome P450, family 1, subfamily A,
polypeptide 1 CYP1A1 −1.40 0.057 1.09 0.583 4.44 0.003∗∗
NM 000941 P450 (cytochrome) oxidoreductase POR −1.93 0.174 1.26 0.367 −2.70 0.122
NM 001979 Epoxide hydrolase 2, cytoplasmic EPHX2 −2.06 0.066 −2.24 0.225 −1.22 0.369
NM 000773 Cytochrome P450, family 2, subfamily E,
polypeptide 1 CYP2E1 — — — — — —
NM 000780 Cytochrome P450, family 7, subfamily A,
polypeptide 1 C Y P 7 A 1 ——————
NM 002021 Flavin-containing monooxygenase FMO1 — — — — — —
Heat shock
NM 005347 Heat shock 70kDa protein 5
(glucose-regulated protein, 78kDa) HSPA5 1.35 0.004∗∗ 1.24 0.026∗∗ −1.00 0.983
NM 007034 DnaJ (Hsp40) homolog, subfamily B,
member 4 DNAJB4 1.32 0.052 1.10 0.568 −1.02 0.813
NM 001539 DnaJ (Hsp40) homolog, subfamily A,
member 1 DNAJA1 1.29 0.048∗∗ 1.12 0.439 −1.08 0.443
NM 005526 Heat shock transcription factor 1 HSF1 1.14 0.074 1.08 0.253 1.13 0.354
NM 006644 Heat shock 105kDa/110kDa protein 1 HSPH1 1.14 0.253 1.03 0.551 1.03 0.612
NM 001
040
141
Heat shock protein 90kDa alpha (cytosolic),
class A member 2 HSP90AA2 1.08 0.200 1.05 0.557 1.09 0.279
NM 002157 Heat shock 10kDa protein 1 (chaperonin 10) HSPE1 1.07 0.414 −1.06 0.367 −1.07 0.503
NM 002156 Heat shock 60kDa protein 1 (chaperonin) HSPD1 1.06 0.671 −1.15 0.312 −1.08 0.406
NM 006597 Heat shock 70kDa protein 8 HSPA8 1.02 0.922 −1.09 0.599 −1.33 0.060
NM 021979 Heat shock 70kDa protein 2 HSPA2 1.01 0.908 −1.40 0.004∗∗ −1.46 0.003∗∗
NM 002154 Heat shock 70kDa protein 4 HSPA4 −1.06 0.523 −1.47 0.036∗∗ −1.71 0.004∗∗
NM 007355 Heat shock protein 90kDa alpha (cytosolic),
class B member 1 HSP90AB1 −1.07 0.666 1.00 0.995 −1.61 0.058Journal of Toxicology 5
Table 1: Continued.
GeneBank
accession no. Gene name Symbol
Fold change
Control
media
+P Q
P value NAC
+P Q P value LNAC
+P Q P value
NM 005345 Heat shock 70kDa protein 1A HSPA1A −1.09 0.478 −1.29 0.102 1.00 0.957
NM 001540 Heat shock 27kDa protein 1 HSPB1 −1.24 0.227 −1.00 0.924 −1.28 0.218
NM 005527 Heat shock 70kDa protein 1-like HSPA1L −1.29 0.084 −1.65 0.032∗∗ −1.42 0.077
NM 002155 Heat shock 70kDa protein 6 (HSP70B ) H S P A 6——————
Proliferation/carcinogenesis
NM 001964 Early growth response 1 EGR1 1.97 0.039∗∗ 1.70 0.117 −1.24 0.395
NM 005190 Cyclin C CCNC 1.30 0.226 1.02 0.995 1.18 0.561
NM 182649 Proliferating cell nuclear antigen PCNA 1.14 0.283 −1.08 0.461 −1.04 0.678
NM 053056 Cyclin D1 CCND1 −1.03 0.885 −1.28 0.225 −1.02 0.803
NM 004060 Cyclin G1 CCNG1 −1.05 0.410 −1.02 0.316 1.07 0.435
NM 005225 E2F transcription factor 1 E2F1 −1.28 0.473 −1.16 0.450 −1.94 0.107
Growth arrest/senescence
NM 004864 Growth diﬀerentiation factor 15 GDF15 1.91 0.000∗∗ 1.96 0.003∗∗ 1.37 0.045∗∗
NM 004083 DNA-damage-inducible transcript 3 DDIT3 1.87 0.000∗∗ 2.17 0.000∗∗ 1.46 0.020∗∗
NM 000389 Cyclin-dependent kinase inhibitor 1A (p21,
Cip1) CDKN1A 1.50 0.002∗∗ 1.72 0.001∗∗ 1.88 0.000∗∗
NM 001924 Growth arrest and DNA-damage-inducible,
alpha GADD45A 1.29 0.125 1.50 0.044∗∗ −1.01 0.942
NM 002392 Mdm2, transformed 3T3 cell double minute
2, p53-binding protein (mouse) MDM2 1.26 0.119 −1.01 0.999 1.25 0.112
NM 000546 Tumor protein p53 TP53 1.14 0.294 −1.10 0.546 −1.11 0.353
NM 002178 Insulin-like growth factor-binding protein 6 IGFBP6 −1.19 0.186 1.04 0.761 −1.58 0.032∗∗
Inﬂammatory
NM 001562 Interleukin 18 (interferon-gamma-inducing
factor) IL18 1.49 0.010∗∗ 1.26 0.106 1.28 0.016∗∗
NM 000575 Interleukin 1, alpha IL1A 1.47 0.085 1.18 0.481 1.88 0.020∗∗
NM 000602
Serpin peptidase inhibitor, clade E (nexin,
plasminogen activator inhibitor type 1),
member 1
SERPINE1 1.38 0.035∗∗ 1.34 0.096 1.01 0.976
NM 000595 Lymphotoxin alpha (TNF superfamily,
member 1) LTA 1.22 0.458 1.38 0.141 −2.19 0.060
NM 003998 Nuclear factor of kappa light polypeptide
gene enhancer in B cells 1 (p105) NFKB1 1.22 0.004∗∗ 1.12 0.092 1.36 0.000∗∗
NM 002415 Macrophage migration inhibitory factor
(glycosylation-inhibiting factor) MIF 1.02 0.505 1.13 0.043∗∗ −1.06 0.331
NM 000576 Interleukin 1, beta IL1B −1.02 0.948 −1.69 0.357 −1.02 0.936
NM 002989 Chemokine (C-C motif) ligand 21 CCL21 — — — — — —
NM 002983 Chemokine (C-C motif) ligand 3 CCL3 — — — — — —
NM 002984 Chemokine (C-C motif) ligand 4 CCL4 — — — — — —
NM 001565 Chemokine (C-X-C motif) ligand 10 CXCL10 — — — — — —
DNA damage/repair
NM 000051 Ataxia telangiectasia mutated ATM 1.21 0.318 −1.38 0.197 −1.07 0.727
NM 005431 X-ray repair complementing defective repair
in Chinese hamster cells 2 XRCC2 1.19 0.125 −1.26 0.261 1.10 0.303
NM 003362 Uracil-DNA glycosylase UNG 1.11 0.315 −1.01 0.882 −1.01 0.8906 Journal of Toxicology
Table 1: Continued.
GeneBank
accession no. Gene name Symbol
Fold change
Control
media
+P Q
P value NAC
+P Q P value LNAC
+P Q P value
NM 000122
Excision repair cross-complementing rodent
repair deﬁciency, complementation group 3
(xeroderma pigmentosum group B
complementing)
ERCC3 1.07 0.612 −1.26 0.271 −1.20 0.229
NM 005053 RAD23 homolog A (S. cerevisiae) RAD23A 1.04 0.764 −1.00 0.956 −1.23 0.265
NM 007194 CHK2 checkpoint homolog (S. pombe) CHEK2 1.03 0.844 −1.32 0.111 −1.23 0.100
NM 001923 Damage-speciﬁc DNA-binding protein 1,
127kDa DDB1 −1.11 0.403 −1.26 0.241 −1.54 0.041∗∗
NM 001983
Excision repair cross-complementing rodent
repair deﬁciency, complementation group 1
(includes overlapping antisense sequence)
ERCC1 −1.16 0.463 1.08 0.666 −1.48 0.278
NM 006297 X-ray repair complementing defective repair
in Chinese hamster cells 1 XRCC1 −1.25 0.235 −1.29 0.226 −1.64 0.071
NM 007120 UDP glucuronosyltransferase 1 family,
polypeptide A4 UGT1A4 −1.30 0.319 −2.04 0.071 −1.50 0.283
Apoptosis signalling
NM 001230 Caspase 10, apoptosis-related cysteine
peptidase CASP10 1.71 0.006∗∗ 1.25 0.194 1.35 0.110
NM 001154 Annexin A5 ANXA5 1.42 0.025∗∗ 1.17 0.073 1.42 0.004∗∗
NM 020529 Nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha NFKBIA 1.20 0.097 1.35 0.014∗∗ 1.47 0.017∗∗
NM 001228 Caspase 8, apoptosis-related cysteine
peptidase CASP8 1.15 0.184 −1.08 0.571 1.36 0.017∗∗
NM 004324 BCL2-associated X protein BAX −1.04 0.656 −1.12 0.503 −1.30 0.069
NM 003810 T u m o rn e c r o s i sf a c t o r( l i g a n d )s u p e r f a m i l y ,
member 10 TNFSF10 −1.09 0.788 −1.15 0.444 −1.53 0.110
NM 033292 Caspase 1, apoptosis-related cysteine
peptidase (interleukin 1, beta, convertase) CASP1 −1.11 0.818 −1.24 0.150 −1.19 0.627
NM 001065 T u m o rn e c r o s i sf a c t o rr e c e p t o rs u p e r f a m i l y ,
member 1A TNFRSF1A −1.29 0.235 −1.15 0.610 −1.64 0.081
NM 138578 BCL2-like 1 BCL2L1 −1.46 0.028∗∗ −1.37 0.257 −1.42 0.340
Housekeeping
NM 001101 Actin, beta ACTB 1.35 0.018∗∗ −1.17 0.251 1.23 0.152
NM 004048 Beta-2-microglobulin B2M — — — — — —
NM 000194 Hypoxanthine phosphoribosyltransferase 1
(Lesch-Nyhan syndrome) H P R T 1——————
NM 012423 Ribosomal protein L13a RPL13A — — — — — —
NM 002046 Glyceraldehyde-3-phosphate dehydrogenase GAPDH — — — — — —
∗∗P<. 05.
PQ for 4h was signiﬁcantly decreased relative to untreated
control cells and was further decreased following 1.0mM PQ
challenge.PretreatmentwithL-NACwaseﬀectiveinprevent-
ing the decreases of mitochondrial membrane potential in
both 0.25 and 1.0mM PQ-challenged cells, returning it to
basal levels in the former, as well as increasing it nearly 2-
fold when compared to untreated control cells (Figure 4).
Conversely, pretreatment with NAC only signiﬁcantly pre-
vented the decrease in mitochondrial membrane potential of
0.25mM PQ-challenged cells, having no apparent eﬀect on
untreated control or 1.0mM PQ-challenged cells.
3.6. Eﬀe c to fN A Co rL - N A CP r e t r e a t m e n to nt h eS e c r e t i o n
of Inﬂammatory Cytokines after PQ Challenge. Levels of IL-
8 secreted by cells exposed to 0.25mM and 1.0mM PQJournal of Toxicology 7
Table 2: Relative expression, via conventional RT-PCR analysis, of genes involved with cellular stress and toxicity in cells challenged with
0.25mM PQ for 4h following pretreatment with control on NAC-, L-NAC- or EL-containing media. Fold change is expressed relative to the
respective untreated time control using the housekeeping gene RPL13A. n = 3 independent experiments performed in triplicate.
GeneBank
accession no. Gene name Symbol
Fold change
Control
media
+P Q
P-value NAC
+P Q P-value LNAC
+P Q P-value EL +
PQ
P-value
Miscellaneous genes
NM 00584 Interleukin 8 IL8 2.23 0.007∗∗ 2.01 0.001∗∗ 1.74 0.010∗∗ 2.15 0.009∗∗
NM 002746 Mitogen-activated protein kinase 3 MAPK3 1.47 0.404 1.45 0.472 1.86 0.151 1.55 0.378
NM 002228 Jun oncogene JUN 1.40 0.240 1.63 0.049∗∗ 1.36 0.174 1.09 0.606
NM 002750 Mitogen-activated protein kinase 8 MAPK8 1.18 0.847 1.45 0.544 1.03 0.907 −1.08 0.820
NM 000660 Transforming growth factor, beta 1 TGFB1 1.13 0.593 1.34 0.245 1.26 0.316 1.07 0.664
NM 005252 V-fos FBJ murine osteosarcoma viral
oncogene homolog FOS 1.02 0.866 1.63 0.417 1.09 0.958 1.04 0.737
NM 001315 Mitogen-activated protein kinase 14 MAPK14 −1.03 0.781 1.24 0.590 −1.01 0.930 −1.33 0.911
NM 000572 Interleukin 10 IL10 −2.15 0.079 −1.82 0.126 1.09 0.889 −1.60 0.177
Veriﬁcation Genes
NM 000576 Interleukin 1, beta IL1B 1.35 0.677 1.73 0.476 1.77 0.452 1.40 0.656
NM 020529
Nuclear factor of kappa light
polypeptide gene enhancer in B-cells
inhibitor, alpha
NFKBIA 1.31 0.271 1.46 0.179 1.69 0.087 1.55 0.205
NM 000499 Cytochrome P450, family 1,
subfamily A, polypeptide 1 CYP1A1 1.12 0.950 1.10 0.925 2.26 0.155 1.77 0.400
NM 000575 Interleukin 1, alpha IL1A 1.08 0.802 1.48 0.308 1.65 0.317 1.36 0.446
NM 000594 Tumor necrosis factor (TNF
superfamily, member 2) TNF −1.00 0.942 1.34 0.255 1.32 0.134 1.36 0.098
NM 000454
Superoxide dismutase 1, soluble
(amyotrophic lateral sclerosis 1
(adult))
SOD1 −1.04 0.962 1.02 0.784 −1.43 0.263 −1.24 0.297
NM 001752 Catalase CAT −1.12 0.852 −1.21 0.402 −1.30 0.299 −1.25 0.466
∗∗P<. 05.
were signiﬁcantly increased relative to untreated control cells
(Figure 5). Both NAC and L-NAC pretreatments decreased
IL-8 levels in untreated control cells and 0.25mM PQ-
challenged cells, while L-NAC, but not NAC, was also able
to signiﬁcantly reduce levels of IL-8 following 1.0mM PQ
challenge. Levels of IL-1β, IL-6, IL-10, IL15, TNF-α,a n d
eotaxin were not reliably detectable under these conditions.
3.7. Eﬀect of NAC or L-NAC Pretreatment on Cellular Gene
Expression following PQ Challenge. Changes in gene expres-
sion were assessed using a gene array designed to study genes
involved with cellular stress and toxicity. The magnitude of
gene expression in cells pretreated with NAC or L-NAC prior
to 0.25mM PQ challenge for 4h was generally decreased
relative to challenged cells with no pretreatment (Figure 6).
Fold changes (relative to control cells) of each gene of the
array following PQ challenge with no pretreatment, NAC
pretreatment, or L-NAC pretreatment are listed in Table 1.
The expression of many oxidative or metabolic stress-
related genes was not signiﬁcantly altered under any of
the studied conditions, with the exception of CYP1A1 and
PTGS1beingsigniﬁcantlyupregulatedinPQ-challengedcells
pretreated with L-NAC. The expression of all studied heat
shock genes remained more or less unchanged in PQ-treated
cellsbutHSPA2,HSPA4,andHSPA1Lwereeachsigniﬁcantly
downregulated with NAC or L-NAC pretreatment. The
expression of EGR1 was increased 2.0-fold in PQ challenged
cells in the absence of antioxidant pretreatment but its
expression was maintained at control levels with L-NAC
pretreatment.
Antioxidant pretreatment of cells subsequently chal-
lenged with PQ had an eﬀect on genes related to growth
arrest and senescence as well. Brieﬂy, GDF15 and DDIT3
were both signiﬁcantly upregulated 1.9-fold following PQ
challenge and were modulated with L-NAC (1.4- and
1.5-fold, resp.), but not NAC (2.0- and 2.2-fold, resp.),
pretreatment. CDKN1A was upregulated 1.5-fold following
PQ challenge and was progressively upregulated further with
both NAC (1.7-fold) and L-NAC (1.9-fold) pretreatment.
Also signiﬁcantly altered were the expression patterns of
several inﬂammatory genes. IL18 was upregulated 1.5-fold8 Journal of Toxicology
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Figure 1: Eﬀect of NAC on the cell viability (a) and uptake of NAC
(b) in A549 cells. The viability of cells treated for 24h with increas-
ing concentrations of NAC was assessed using the MTT assay. Bars
represent mean ± S.E.M. of 3 independent experiments performed
in octuplet. ∗denotes signiﬁcant diﬀerence relative to control (P<
.05). For the uptake studies (b), cells were treated with either
5.0mM NAC- or L-NAC-containing media for various time-points
up to 24h; intracellular NAC levels were measured with a UPLC
method as described in Section 2. (solid line: NAC treatment; dot-
ted line: L-NAC treatment). Data points represent mean ± S.E.M.
of 3 independent experiments performed in duplicate. †denotes
signiﬁcant diﬀerence relative to NAC-treated group (P<. 05).
in PQ-challenged cells, but its expression was modulated
with NAC or L-NAC pretreatment. Using individual primer
assays with conventional RT-PCR, we found IL8 to be
signiﬁcantly upregulated (2.2-fold) in PQ-challenged cells
with no pretreatment, but it was progressively modulated
with NAC (2.0-fold) and L-NAC (1.7-fold) pretreatment. It
is worth noting that the IL10 gene, which codes for the anti-
inﬂammatory cytokine IL-10, was down-regulated in PQ-
challenged cells, an eﬀect reversed by L-NAC, but not NAC,
pretreatment. Finally, the expression of many apoptosis
signalling genes was not altered under the studied conditions
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Figure 2: Eﬀect of EL, NAC, or L-NAC pretreatment on viability
of PQ-challenged cells. The viability of cells pretreated with control
media (no pretreatment), or 5.0mM NAC- (NAC Pretreatment), L-
NAC- (L-NAC pretreatment) or empty liposome-containing media
(EL pretreatment) for 4h prior to 24h PQ challenge (0, 0.1, 0.5, or
1.0mM) was assessed using the MTT assay. Bars represent mean
± S.E.M. of 3 independent experiments performed in octuplet.
∗denotes signiﬁcantdiﬀerence relative to cells with no pretreatment
(P<. 05); N.D.: not determined.
with the exception of CASP10, which was upregulated
1.7-fold in PQ-challenged cells with no pretreatment and
was modulated by both NAC and L-NAC pretreatment.
The eﬀect of L-NAC was conﬁrmed to not be a direct
result of the lipids composing the liposomes as pretreat-
ment with empty liposomes did not alter the expression
compared to PQ-challenged cells with no pretreatment
(Table 2).
Conventional RT-PCR assays were performed to validate
ﬁndings obtained from the gene arrays. Similar gene expres-
sion patterns were observed for the majority of the genes
(e.g., CAT, CYP1A1, IL1A, NFKBIA, and SOD1) analyzed by
both methods.
3.8. Validation of Gene Array Data Using Conventional RT-
PCR. Figure 7 depicts a representative electropherogram of
extracted RNA, achieved using the Experion automated
electrophoresis station, indicating high RNA integrity with
little or no apparent degradation of 18 and 28S rRNA.
Additionally, a single peak (or zero if no product was
ampliﬁed) was present in ﬁrst-derivative dissociation curves
for every PCR reaction on all gene arrays and conventional
RT-PCR assays, indicating that only a single PCR product
(i.e., the gene of interest) was ampliﬁed in each case.
3.9.EﬀectsofEmptyLiposomesonCytotoxicityandGeneArray
Analysis. Challenge of A549 cells with empty liposomes was
not toxic to cells. Also, pretreatment of cells with empty
liposomes did not confer any protection against PQ-induced
cytotoxicity (Figure 2) and gene array analysis (Table 2).Journal of Toxicology 9
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Figure 3: Eﬀect of NAC or L-NAC pretreatment on intracellular levels of GSH (a), PQ (b), and ROS (c) in PQ-challenged cells. Cells
pretreated for 4h with control media (No Pretreatment) or 5.0mM NAC- (NAC Pretreatment) or L-NAC-containing media (L-NAC
Pretreatment) were challenged with increasing PQ concentrations (0, 0.1, 0.5, 1.0, and 5.0mM) for 24h. Cells were harvested and lysed
for concomitant measurement of intracellular GSH content (a) and PQ uptake (b) via UPLC analysis and normalized to total protein. For
the measurement of ROS, cells were stained for 30min posttreatment with the cell permeable CM-H2DCFDA ﬂuorescent dye speciﬁc for
oxidative species. Adherent cells were scraped and analyzed ﬂow cytometrically using the FL1-H channel. Bars represent mean ± S.E.M. of 3
independent experiments. ∗denotes signiﬁcant diﬀerence relative to cells with no pretreatment (P<. 05).
4. Discussion
The results of the present study showed that exposure of
A549 cells to PQ in vitro resulted in a concentration- and
time-dependent accumulation of PQ which was associated
with concomitant increases in the intracellular levels of ROS
and decreases in GSH levels, conﬁrming results from other
studies that PQ exerts its toxic eﬀects, to a major extent, via
oxidative stress mechanisms [1–3, 26]. Accordingly, research
eﬀorts in the management of PQ poisoning are also directed
towards the use of antioxidants. A potential antioxidant
candidate is NAC because not only it is available in the
clinicbutalsoitsthiolgroupprovidesfreeradical-scavenging
properties and it acts as a source of cysteine, often the
limiting precursor of de novo GSH synthesis [3, 17, 18].
In order to assess the cytoprotective eﬀects of both
the conventional and liposomal NAC formulations, we ﬁrst
investigatedtheiroptimaltreatmentconditionsinA549cells.
NAC has been reported to exhibit cytotoxicity at variable
concentrations depending on cell type: 10mM NAC was10 Journal of Toxicology
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Figure 4: Eﬀect of NAC or L-NAC pretreatment on mitochondrial
membrane potential following PQ challenge. Cells pretreated for
4h with control media or 5.0mM NAC- (N) or L-NAC-containing
media (L) were challenged with 0, 0.25, or 1.0mM PQ for 4h. Cells
were stained for 30min posttreatment with the cell permeable JC-
1 ﬂuorescent dye. Bars represent mean ± S.E.M. of 3 independent
experiments. ∗denotes signiﬁcant diﬀerence relative to cells with no
pretreatment (P<. 05).
nontoxicinhumanbronchialepithelialcells[17],40mMwas
nontoxic in 3T3 ﬁbroblasts [27], and 50mM was nontoxic in
aortic endothelial cells [17]; however, 30mM was cytotoxic
invascularsmoothmusclecells,monocytes,andneutrophils,
and as low as 5.0mM NAC was cytotoxic in porcine aortic
endothelial cells [17]. Studies involving NAC in A549 cells
have generally employed concentrations ranging from 1 to
10mM [26, 28–31]. Our results indicate that concentrations
of 10.0mM or less had no negative impact on cell viability,
while a greater concentration (i.e., 50.0mM) resulted in
signiﬁcantly decreased cell viability after 24h (Figure 1).
Both NAC formulations conferred protection against
PQ-induced cytotoxicity but generally L-NAC was more
eﬀective than the conventional NAC formulation in limiting
the PQ-induced decreases of cellular GSH content (Figure
3(a)) and production of ROS (Figure 3(c)). The protective
eﬀect of NAC or L-NAC cannot be attributed to the eﬀect
of the antioxidant formulations on PQ uptake since NAC
or L-NAC pretreatment had no eﬀect on intracellular PQ
levels in A549 cells (Figure 3(b)). It is unclear whether
this protective eﬀect is a result of NAC’s direct scavenging
properties or the de novo synthesis of GSH using NAC as
a precursor. The possible reason for the protective eﬀects
being more prominent in cells pretreated with L-NAC was
the greater and more sustainable intracellular NAC levels
that can be achieved via liposomal delivery (Figure 1(b)).
Cellular uptake experiments showed that the uptake of NAC
as a liposomal formulation was much greater (i.e., up to
4-fold) under all conditions studied when delivered as L-
NAC compared to NAC (Figure 1(b)). Thus, the higher and
more sustained intracellular NAC levels are responsible for
maintaining a normal cellular redox status as evidenced
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Figure 5: Eﬀect of NAC or L-NAC pretreatment on IL-8 levels after
PQ exposure. Cells pretreated for 4h with control media or 5.0mM
NAC- (N) or L-NAC-containing media (L) were challenged with 0,
0.25, or 1.0mM PQ for 4h. Cell culture supernatants were collected
immediately following challenge and concomitantly analyzed for
IL-8 using the Bio-Plex suspension array system. Bars represent
mean ± S.E.M. of 3 independent experiments. ∗denotes signiﬁcant
diﬀerence relative to cells with no pretreatment (P<. 05).
by the reduced production of ROS and higher GSH levels.
It should be noted that pretreatment of cells with empty
liposomes consisting of DPPC lipids did not alter the PQ-
induced changes in cytotoxicity and gene expression.
The mitochondria are thought to be essential targets of
PQ and important in its toxicity. In fact, there is evidence
that PQ disrupts the mitochondrial electron transfer chain
resulting in a reduction of metabolic function, and it
is suggested that lesions due to PQ ﬁrst occur in the
mitochondria [32–34]. Pretreatment with NAC or L-NAC
exhibited a beneﬁcial eﬀect on the mitochondrial membrane
potential of PQ-challenged cells (Figure 4). NAC or L-
NAC pretreatment increased the membrane potential above
control levels in 0.25mM PQ-challenged cells for 4h, while
L-NAC, but not NAC, pretreatment limited the decrease
of membrane potential in cells exposed to 1.0mM PQ.
Interestingly, control cells pretreated with L-NAC exhibited
nearly a 2-fold increase in ﬂuorescence intensity relative
to control cells with no pretreatment. Suntres et al. [8]
haveshownthatradioactively-labelledliposomalantioxidant
vesicles were associated with mitochondria, and antioxidants
that are selectively accumulated into mitochondria can
inhibit mitochondrial oxidative damage that contributes to
a range of degenerative diseases related to oxidative stress.
The maintenance of cellular redox status is crucial for
cellular homeostasis, and its dysregulation towards a more
oxidized intracellular environment is associated with aber-
rant transcriptional activation and gene expression aﬀecting
s e v e r a lp r o c e s s e ss u c ha sc e l lg r o w t h ,d i ﬀerentiation, and
inﬂammation [22, 35–37]. In this study, the magnitude of
PQ-induced changes in gene expression in cells pretreated
with NAC or L-NAC prior to 0.25mM PQ challenge forJournal of Toxicology 11
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Figure 7: Validation of RNA integrity (a) and assessment of
PCR gene product quality (b). Aliquots of extracted RNA from
control or PQ-challenged A549 cells with or without pretreat-
ment were assessed for RNA concentration and integrity using
the Experion automated electrophoresis station. A representative
electropherogram displays 18 and 28S rRNA peaks. Representative
ﬁrst-derivative dissociation curves of ampliﬁed PCR product of 4h
control and PQ-challenged cells pretreated with control media or
NAC- or L-NAC-containing media are depicted.
4h was generally lower with the L-NAC being a more
eﬀective treatment than NAC (Figure 6). Although the
exact mechanism(s) by which NAC aﬀected the pathways
involved in signal transduction and gene expression cannot
be delineated from the results of this study, it is possible that
these pathways are regulated by oxidants and redox-sensitive
steps since increasing levels of intracellular NAC aﬀect the
steady state level of oxidants (Figure 3(c)) and can modify
the redox status of the cell (Figure 3), an eﬀect known to
exert a regulatory eﬀect on transcriptional activation and
gene expression [22, 35, 38–40]. For example, expression
of GDF15, IL8, EGR1, and CASP10 genes is known to
be upregulated in oxidative stress-induced conditions, a
treatmenteﬀectcounteractedbythe presenceofantioxidants
[36, 41–47]. The upregulation of GDF15, a protein that plays
a role in regulating inﬂammatory and apoptotic pathways
in injured tissues and during disease processes [48–50],
and EGR1, which encodes a transcriptional regulator that
activates genes (including p53) required for diﬀerentiation
and mitogenesis [51], was maintained closer to normal levels
in cells pretreated with L-NAC, but not NAC (Table 1). The
expression of CASP10, which codes for the initiator caspase-
10 involved in the death-inducing signaling complex during
apoptosis (Bidere et al. [52]), was upregulated 1.7-fold in
PQ-challenged cells but was closer to control levels in PQ-
challenged cells pretreated with NAC or L-NAC (Table 1).
It is evident that the preservation of cellular homeostasis
by L-NAC, and to a lesser extent by NAC, promoted cell
survival.
Paraquat administration has been shown to be asso-
ciated with an inﬁltration of neutrophils in lung [5, 53].
Interleukin-8 (IL-8), a potent proinﬂammatory cytokine
released in response to injury, has a key role in the recruit-
ment and activation of neutrophils during inﬂammation
[54, 55]. The expression of IL8 gene was upregulated in PQ-
challenged cells, but its expression was substantially modu-
lated with pretreatment of L-NAC and to a lesser extent with
NAC (Table 2). The inhibitory eﬀects of NAC and L-NAC on
IL-8 expression were correlated with comparable changes in
IL-8 protein secretion in the cell culture supernatant of PQ-
challenged cells (Figure 5). The ability of NAC to modulate
the upregulation of IL-8 has been described in other studies
as well: the increased IL-8 gene [56]a n dp r o t e i n[ 57, 58]
expression of PQ-challenged peripheral blood mononuclear
cells was blocked by NAC [57], and NAC administration
was found to inhibit the release of chemotactic factors for
neutrophils and consequently reduce their inﬁltration into
the lungs of PQ-challenged rats [9].12 Journal of Toxicology
Oxidative stress, which occurs when the redox home-
ostasis within the cell is altered, is a key pleiotropic mod-
ulator which may be involved in the upregulation and/or
downregulation of several genes [35, 37]. IL10, which codes
for the anti-inﬂammatory cytokine interleukin-10 (IL-10),
is down-regulated 2.2-fold following PQ-treatment (Table
2), suggesting that the cell may be actively repressing
anti-inﬂammatory mediators in favor of proinﬂammatory
mediators (e.g., IL-8). The ability of NAC to prevent the
downregulation of IL-10, being greater in cells pretreated
with L-NAC than NAC, is an evidence to conﬁrm that the
higher intracellular levels of NAC maintain the redox status
of cells closer to normalcy.
In conclusion, the results of the present study suggest
t h a tp r e t r e a t m e n to fA 5 4 9c e l l sw i t hN A C ,b o t hi ni t s
conventional and liposomal form, conferred cytoprotection
againstPQ-inducedtoxicity.Thiswasmainlyattributedtoits
ability to ameliorate cellular redox status (i.e., intracellular
GSH content and ROS levels) and was independent of PQ
uptake. These protective eﬀects were more evident in cells
pretreated with L-NAC, which is attributed, at least in part,
to the increased NAC levels achieved via liposomal delivery.
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